Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [
PET
[18F]PM-PBB3
fluorine-18
quality control testing
radiosynthesis
tau
Journal
Journal of labelled compounds & radiopharmaceuticals
ISSN: 1099-1344
Titre abrégé: J Labelled Comp Radiopharm
Pays: England
ID NLM: 7610510
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
08
10
2020
received:
19
08
2020
accepted:
09
10
2020
pubmed:
18
10
2020
medline:
20
1
2022
entrez:
17
10
2020
Statut:
ppublish
Résumé
Recently, we produced
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-119Informations de copyright
© 2020 John Wiley & Sons, Ltd.
Références
Wang YT, Edison P. Tau imaging in neurodegenerative diseases using positron emission tomography. Curr Neurol Neurosci Rep. 2019;19(7):45.
Schöll M, Maass A, Mattsson N, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18-33.
Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54(8):1420-1427.
Betthauser T, Lao PJ, Murali D, et al. In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317. J Nucl Med. 2017;58(6):996-1002.
Ng KP, Pascoal TA, Mathotaarachchi S, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9:25.
Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457-468.
Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58.
Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787-800.
Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6):1094-1108.
Wood H. Alzheimer disease: [11C]PBB3-a new PET ligand that identifies tau pathology in the brains of patients with AD. Nat Rev Neurol. 2013;9(11):599.
Shimada H, Kitamura S, Shinotoh H, et al. Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: a [11C]PBB3-PET study. Alzheimers Dement (Amst). 2017;6:11-20.
Kitamura S, Shimada H, Niwa F, et al. Tau-induced focal neurotoxicity and network disruption related to apathy in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2018;89(11):1208-1214.
Shinotoh H, Shimada H, Kokubo Y, et al. Tau imaging detects distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula. Neurology. 2019;92(2):e136-e147.
Ikeda A, Shimada H, Nishioka K, et al. Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features. Mov Disord. 2019;34(4):568-574.
Endo H, Shimada H, Sahara N, et al. In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy. Mov Disord. 2019;34(5):744-754.
Terada T, Yokokura M, Obi T, et al. In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer's disease. J Neurol. 2019;266(9):2186-2196.
Shimada H, Minatani S, Takeuchi J, et al. Heavy tau burden with subtle amyloid β accumulation in the cerebral cortex and cerebellum in a case of familial Alzheimer's disease with APP Osaka mutation. Int J Mol Sci. 2020;21(12):4443.
Moriguchi S, Takahata K, Shimada H, et al. Excess tau PET ligand retention in elderly patients with major depressive disorder. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0766-9
Ono M, Sahara N, Kumata K, et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain. 2017;140(3):764-780.
Hashimoto H, Kawamura K, Igarashi N, et al. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med. 2014;55(9):1532-1538.
Kimura Y, Ichise M, Ito H, et al. PET Quantification of tau pathology in human brain with 11C-PBB3. J Nucl Med. 2015;56(9):1359-1365.
Hashimoto H, Kawamura K, Takei M, et al. Identification of a major radiometabolite of [11C]PBB3. Nucl Med Biol. 2015;42(12):905-910.
Tagai K, Ono M, Kubota M, et al. High-contrast in-vivo imaging of tau pathologies in Alzheimer's disease and non-Alzheimer's disease tauopathies. Neuron. https://doi.org/10.1016/j.neuron.2020.09.042
Zhang MR, Tsuchiyama A, Haradahira T, Yoshida Y, Furutsuka K, Suzuki K. Development of an automated system for synthesizing 18F-labeled compounds using [18F]fluoroethyl bromide as a synthetic precursor. Appl Radiat Isot. 2002;57(3):335-342.
Waki A, Hashimoto H, Suzuki H, et al. Development of an isolator system for PET drug compounding with sterilization and dispensing units. Kakuigaku. 2016;53(1):1-7.